Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections (NCT07220915) | Clinical Trial Compass
Not Yet RecruitingPhase 3
Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections
360 participantsStarted 2025-12
Plain-language summary
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Panzyga for Prevention of Major Infection in Patients with Hypogammaglobulinemia and Autoimmune or Rheumatic Conditions Receiving Treatment with B-cell Depletion Therapy
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
ā. Are ā„18 years of age at time of informed consent, have been diagnosed with a rheumatic or autoimmune condition, received their last BCDT dose within 3 months of Screening, and have the intention to receive BCDT during study participation. Note: Patients with the following indications are eligible: MS, RA, vasculitis/myositis, SLE, SS, IIM, MCTD, UCTD, myasthenia gravis, autoimmune encephalitis, CIDP, and neuromyelitis optica spectrum disorder). Other rheumatic and autoimmune conditions may also be acceptable with approval from the Medical Monitor.
ā. Have hypogammaglobulinemia (IgG levels \<5 g/L as confirmed by the central laboratory).
ā. Are willing and able to provide voluntary written informed consent for participation in the study and to comply with all protocol requirements..
ā. Are willing and able to comply with a highly effective contraception method during and for 30 days after the treatment period. Contraceptive use by men and women of childbearing potential should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Exclusion criteria
ā. Have a history of anaphylaxis or severe systemic response to immunoglobulin, blood, or plasma-derived products, or any Panzyga component
ā. Have a current major infection at Screening or had \>1 major infection within 6 months prior to Baseline
ā. Have a history of thromboembolic events such as deep vein thrombosis, pulmonary embolism, myocardial infarction, ischemic stroke, transient ischemic attack, or peripheral artery disease (Fontaine IV) within 6 months prior to Baseline
ā. Have a known IgA deficiency with antibodies to IgA